search
Back to results

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer. (REMNANT)

Primary Purpose

Non Small Cell Lung Cancer

Status
Suspended
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Afatinib
Immediate surgery
Sponsored by
European Organisation for Research and Treatment of Cancer - EORTC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non Small Cell Lung Cancer focused on measuring NSCLC, Early stage, Phase II, Randomized, EGFR mutated

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Histological or cytological diagnosis of NSCLC;

  • Patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist;
  • Stage I-III (T1a-3, N0-1, M0 according to UICC version 7) NSCLC by local staging criteria potentially treatable by radical (curative) surgery. Patients with T1 tumor at baseline will be limited to 20%;
  • Radiologically measurable disease according to RECIST criteria 1.1; assessed by chest and upper abdomen CT scan within 2 weeks (+1 week) prior to registration); brain CT scan or MRI according to local practice;
  • No prior treatment for NSCLC is allowed;
  • Adequate tissue in terms of quality and quantity for EGFR local testing.

Exclusion Criteria:

  • no adequate bone marrow function within 2 weeks prior to randomization
  • no adequate liver function. Patients with Gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization
  • no adequate renal function within 2 weeks prior to randomization
  • known positivity to human immunodeficiency virus (HIV), hepatitis B or hepatitis C;
  • known history of allergic reactions attributed to compounds of similar chemical or biological composition;
  • history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Neo adjuvant afatinib

    Immediate surgery

    Arm Description

    once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).

    immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).

    Outcomes

    Primary Outcome Measures

    Decrease in cT-stage
    decrease in cT-stage descriptor measured according to RECIST 1.1

    Secondary Outcome Measures

    Response Rate
    proportion of patients whose response is either complete response (CR) or partial response (PR) using RECIST 1.1;
    Change in surgical treatment intent and technique

    Full Information

    First Posted
    June 10, 2015
    Last Updated
    January 21, 2016
    Sponsor
    European Organisation for Research and Treatment of Cancer - EORTC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02470065
    Brief Title
    Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.
    Acronym
    REMNANT
    Official Title
    Resectable EGFR Mutant NSCLC With (or Without) Afatinib as Neoadjuvant Treatment; REMNANT an Exploratory Study of the EORTC Lung Cancer Group
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2016
    Overall Recruitment Status
    Suspended
    Why Stopped
    Study never started
    Study Start Date
    January 2016 (undefined)
    Primary Completion Date
    September 2018 (Anticipated)
    Study Completion Date
    January 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    European Organisation for Research and Treatment of Cancer - EORTC

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage NSCLC will be randomized between ARM A: neoadjuvant afatinib followed by surgery and ARM B: immediate surgery with curative intent.
    Detailed Description
    This is a multicenter, prospective, open-label, randomized, non-comparative, two-arm phase II trial aiming to evaluate afatinib treatment in pre-operative setting in patients with EGFR mutated NSCLC. After signing of the informed consent, patients will be registered and screened for eligibility and upon confirmation of all eligibility criteria, patients will be randomized 1:1 to: Arm A: once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection). Arm B: immediate surgery with curative intent (anatomical resection and systematic lymph node dissection). Response evaluation in the pre-operative arm will be performed through CT scans at baseline, 4 and 8 weeks. The first 5 patients enrolled in arm A will be part of a safety run-in to check that afatinib treatment doesn't delay surgery.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Non Small Cell Lung Cancer
    Keywords
    NSCLC, Early stage, Phase II, Randomized, EGFR mutated

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    38 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Neo adjuvant afatinib
    Arm Type
    Experimental
    Arm Description
    once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).
    Arm Title
    Immediate surgery
    Arm Type
    Active Comparator
    Arm Description
    immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).
    Intervention Type
    Drug
    Intervention Name(s)
    Afatinib
    Intervention Description
    once daily afatinib at a dose of 40 mg for 8 weeks
    Intervention Type
    Procedure
    Intervention Name(s)
    Immediate surgery
    Intervention Description
    anatomical resection and systematic lymph node dissection
    Primary Outcome Measure Information:
    Title
    Decrease in cT-stage
    Description
    decrease in cT-stage descriptor measured according to RECIST 1.1
    Time Frame
    8 weeks
    Secondary Outcome Measure Information:
    Title
    Response Rate
    Description
    proportion of patients whose response is either complete response (CR) or partial response (PR) using RECIST 1.1;
    Time Frame
    8 weeks
    Title
    Change in surgical treatment intent and technique
    Time Frame
    8 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    90 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Histological or cytological diagnosis of NSCLC; Patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist; Stage I-III (T1a-3, N0-1, M0 according to UICC version 7) NSCLC by local staging criteria potentially treatable by radical (curative) surgery. Patients with T1 tumor at baseline will be limited to 20%; Radiologically measurable disease according to RECIST criteria 1.1; assessed by chest and upper abdomen CT scan within 2 weeks (+1 week) prior to registration); brain CT scan or MRI according to local practice; No prior treatment for NSCLC is allowed; Adequate tissue in terms of quality and quantity for EGFR local testing. Exclusion Criteria: no adequate bone marrow function within 2 weeks prior to randomization no adequate liver function. Patients with Gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization no adequate renal function within 2 weeks prior to randomization known positivity to human immunodeficiency virus (HIV), hepatitis B or hepatitis C; known history of allergic reactions attributed to compounds of similar chemical or biological composition; history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Sanjay Popat, PhD
    Organizational Affiliation
    Royal Marsden NHS Foundation Trust
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.

    We'll reach out to this number within 24 hrs